Purpura Treatment Global Market Report 2025

The purpura treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The historical growth has been driven by the introduction of new therapeutic options, increased use of corticosteroids, growth in clinical research initiatives, rising healthcare expenditure, and improvements in hospital facilities.

The purpura treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Future market expansion will be fueled by the development of biologic therapies, rising demand for genetic screening, increased reliance on telehealth for early diagnosis, regulatory incentives for rare disease treatments, and a shift toward customized treatment approaches. Key trends anticipated during the forecast period include progress in gene-based therapies, innovations in cell therapy, precision drug delivery technologies, adoption of wearable diagnostic tools, and advancements in nanotechnology-based medicine.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the purpura treatment market. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, believing they are harmful invaders such as bacteria or viruses. Environmental triggers often contribute to this by promoting inflammation or molecular mimicry, which leads the immune system to attack the body’s own tissues and increases the risk of autoimmune diseases. Treatments for purpura play a crucial role in managing autoimmune diseases by suppressing the overactive immune response, enhancing platelet production, and reducing inflammation in blood vessels. This helps control symptoms like bruising, bleeding, and low platelet counts, which are commonly seen in autoimmune-related purpura such as immune thrombocytopenic purpura (ITP). For example, in March 2023, a report published by the Office for Health Improvement & Disparities, a UK government department, stated that in 2022, 17.6% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition, an increase from 17% in 2021. Thus, the rise in autoimmune disease prevalence is fueling the growth of the purpura treatment market.

The increasing demand for personalized medicine is also expected to boost the purpura treatment market. Personalized medicine involves tailoring medical treatments and practices to individual patients based on their genetic makeup, environmental factors, and lifestyle. This demand is being driven by advances in genomics and biotechnology, which allow for more precise and effective treatments tailored to individual genetic profiles, ultimately improving patient outcomes and minimizing side effects. In the context of purpura, personalized medicine uses genetic and immune system data to customize therapies, thereby improving treatment effectiveness and reducing adverse effects for patients based on their unique biological responses. For instance, according to the Personalized Medicine Coalition, a U.S.-based professional membership organization, in 2022, 12 newly approved personalized medicines accounted for approximately 34% of all new therapies approved that year, reflecting significant growth from previous years. Therefore, the growing interest in personalized medicine is contributing to the expansion of the purpura treatment market.

Leading companies in the purpura treatment market are prioritizing advancements in therapeutic options such as oral spleen tyrosine kinase (SYK) inhibitors to enhance treatment outcomes. These oral SYK inhibitors are medications that block the SYK enzyme, which plays a key role in the immune system’s signaling processes. For example, in April 2023, Kissei Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, introduced TAVALISSE tablets (100 mg and 150 mg) in Japan as an oral treatment for adult patients with chronic idiopathic thrombocytopenic purpura (ITP). TAVALISSE (fostamatinib sodium hydrate) works by inhibiting the destruction of platelets by macrophages, thus improving bleeding symptoms in chronic ITP patients. It was approved in Japan following a Phase 3 clinical trial (R788-1301), where 36% of patients achieved a stable platelet response compared to 0% in the placebo group, demonstrating its effectiveness as a new treatment option.

Major players in the purpura treatment market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Limited, Intas Pharmaceuticals Ltd., Biogen Inc., Chugai Pharmaceutical Co Ltd., Sun Pharmaceutical Industries Limited, Octapharma AG, Grifols S.A., GC Pharma, Emergent BioSolutions Inc., Kissei Pharmaceutical Co Ltd., Ablynx N.V., Shire plc, Lee's Pharmaceutical Holdings Limited, Omeros Corporation, and KM Biologics Co Ltd.

North America was the largest region in the purpura treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in purpura treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the purpura treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Purpura treatment refers to the medical care and management of purpura, which are purple-colored spots or patches on the skin caused by small blood vessels leaking under the skin. Purpura treatment is utilized by healthcare providers to manage symptoms and address underlying conditions such as platelet disorders, infections, or autoimmune diseases that cause bleeding under the skin.

The main types of purpura treatment include non-thrombocytopenic purpura, thrombocytopenic purpura, and allergic purpura. Non-thrombocytopenic purpura is characterized by bleeding under the skin, resulting in red or purple discoloration (purpura). These conditions are managed through different treatment approaches, such as topical therapies, oral medications, intravitreal injections, laser treatments, and photodynamic therapy. Purpura may present as either acute or chronic cases and is distributed through several channels, including hospital pharmacies, online pharmacies, and retail pharmacies. The treatments are utilized by various end users, such as hospitals, clinics, and other healthcare facilities.

The purpura treatment market research report is one of a series of new reports that provides purpura treatment market statistics, including purpura treatment industry global market size, regional shares, competitors with a purpura treatment market share, purpura treatment market segments, market trends and opportunities, and any further data you may need to thrive in the purpura treatment industry. This purpura treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The purpura treatment market consists of revenues earned by entities by providing services such as diagnostic evaluations, immunosuppressive therapy, intravenous immunoglobulin (IVIG) infusions, platelet transfusions, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The purpura treatment market also includes sales of products including corticosteroids, immunoglobulins (IVIG), biologics, immunosuppressants, and diagnostic kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.